Frontier IP Group Nandi Proteins led consortium wins UK grant

Frontier IP chief executive officer Neil Crabb said: “This grant from the UK’s leading charity dedicated to helping people who need to live without gluten and the involvement of three major industry partners represents very strong validation for Nandi’s novel technology. We look forward to the day when sufferers of the disease or those simply looking to avoid gluten can enjoy a high-quality loaf of bread.

“However, replacing gluten is only one of many potential applications for the technology. Others include replacing a wide range of additives, sugar and fat in a whole host of processed foods, from cakes to meats. We are pushing on with development.”

Frontier IP Group (LON:FIPP), a specialist in commmercialising university intellectual property, today announces that a consortium led by portfolio company Nandi Proteins has won funding for Coeliac UK and Innovate UK to develop gluten replacements for use in bread from faba beans, oats and rapeseed by-products. Frontier IP holds a 20.7 per cent stake in the Company.

Highlights

· £250,000 project to create new ingredients to improve the taste and texture of gluten-free bread using Nandi Proteins’ patented technology wins £180,697 grant from Coeliac UK and Innovate UK, the UK’s innovation agency

· Strong industrial involvement: commercial partners in consortium are Genius Foods, Agrii, part of Origin Enterprises plc, and AB Mauri, a subsidiary of FTSE 100 group Associated British Foods plc; academic partner is Heriot-Watt University

· Gluten replacements will be derived from faba beans, oats and rapeseed by-products. All crops are grown in the UK and are underused by the food industry

The Charity and Innovate UK are supporting the £250,000 project with a £180,697 grant as part of a strategy to encourage manufacturers to extend their gluten-free product ranges. Consortium members include two food companies, gluten-free specialist Genius Foods and global ingredients business AB Mauri, part of FTSE 100 group AB Foods, and a major UK agronomy firm Agrii, a subsidiary of agri-services group Origin Enterprises. Heriot-Watt University, Edinburgh, will provide food science research facilities.

The project will see Heriot-Watt spin out Nandi use its patented processing technology (see below for an explanation) to create protein concentrates from natural raw materials supplied by Agrii. These materials include faba beans, a naked oat variety with a high protein content and rapeseed press cake (the residual seed material left once oil has been extracted) currently used as animal feed. Genius Foods and AB Mauri will then test the ingredients, adapt their bread formulations, and assess commercial feasibility.

Gluten, a protein found in wheat flour, is the main reason for bread dough’s strength and elasticity. However, people with coeliac disease, a lifelong autoimmune condition, must have a gluten-free diet. Replacements are hard to find. Many industrial gluten-free bread formulations use additives such as xanthan gum to improve structure and result in loaves with poor taste, inferior texture and lower protein content.

It is estimated that one per cent of the UK population is gluten intolerant and 15 per cent of households are looking to remove gluten from their diets.

Nandi’s technology is also being used to develop novel ingredients to replace a range of other additives, fat and sugar in processed foods.

Coeliac UK chief executive Sarah Sleet said: “Coeliac UK is a world leader on coeliac disease, supporting research that makes a real-world impact. The research on innovative gluten-free ingredients will keep the UK ahead in the food industry’s expansion into gluten free.”

Dr Kath Mackay, Director of Ageing Society, Health and Nutrition at Innovate UK, said: “Stimulating innovation in our food and health sectors are crucial components of the government’s industrial strategy. By working with Coeliac UK, we will be able to offer funding that results in improved quality of life for people with this condition and support and stimulate our vibrant health care and food technology sectors.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018,

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence

    Frontier IP Group Plc

    Rallybio forges joint venture with U.K. tech firm

    A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom. Rallybio, focused on rare diseases, has not yet publicly

    Frontier IP Group Plc

    What is leptospirosis and how can it harm us and our pets?

    Recently reported cases of the often fatal bacterial infection leptospirosis in dogs in Sydney have raised the issue of animal diseases that also affect humans. This zoonotic disease is spread by rats and other rodents. However, this

    Frontier IP Group Plc

    The Robot Uprising Is Here

    The robot uprising is inevitable. Take the world’s first raspberry-picking robot, an autonomous machine that’s in development by Fieldwork Robotics at the University of Plymouth in the UK. This fruit-picking Terminator, so to speak, was developed for

    Frontier IP Group Plc

    The UK’s 50 Most Disruptive Companies Revealed

    After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging

    Frontier IP Group Plc

    Artificial intelligence in the world of drug discovery

    Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the

    Frontier IP Group Plc

    11 diseases which can cause infection

    Illnesses that can pass from animals to humans are known as zoonotic. They’re surprisingly common: More than six out of every 10 known infectious diseases in people are actually contracted from animals, according to the CDC.